We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Neurotech International is a medical devices business based in Australia. Neurotech International shares (NTI) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Neurotech International has a trailing 12-month revenue of around $393,964. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| 52-week range | $0.038 - $0.075 |
|---|---|
| 50-day moving average | $0.0564 |
| 200-day moving average | $0.0547 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.07
| 1 week (2022-06-24) | 0.07 |
|---|---|
| 1 month (2022-06-01) | 16.67% |
| 3 months (2022-04-01) | 20.69% |
| 6 months (2021-12-31) | 16.67% |
| 1 year (2021-07-01) | 29.63% |
|---|---|
| 2 years (2020-07-01) | 600.00% |
| 3 years (2019-07-01) | 233.33% |
| 5 years (2017-06-30) | -68.01% |
| Revenue TTM | $393,964 |
|---|---|
| Gross profit TTM | $245,876 |
| Return on assets TTM | -131.55% |
| Return on equity TTM | -235.49% |
| Profit margin | 0% |
| Book value | 0.004 |
| Market capitalisation | $48.1 million |
TTM: trailing 12 months
We're not expecting Neurotech International to pay a dividend over the next 12 months.
Over the last 12 months, Neurotech International 's shares have ranged in value from as little as $0.038 up to $0.075. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Neurotech International 's is 2.6834. This would suggest that Neurotech International 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on developing neurostimulation and neurodiagnostic solutions to be delivered through the Mente platform, a platform technology to enable medical practitioners to remotely monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
